AHA and ACC Update Cardiovascular Management Guideline for Noncardiac Surgery
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 1, 2024 -- In a clinical practice guideline issued by the American College of Cardiology and American Heart Association, published online Sept. 24 in both Circulation and the Journal of the American College of Cardiology, updated recommendations are presented for the perioperative cardiovascular management of noncardiac surgery.
Annemarie Thompson, M.D., from Duke University Hospital in Durham, North Carolina, and colleagues note that a stepwise approach to perioperative cardiac assessment can help clinicians determine whether surgery should proceed or whether a pause for additional evaluation is necessary. For patients undergoing noncardiac surgery, cardiovascular screening and treatment should adhere to the same indications as for nonsurgical patients, with careful timing to avoid delays in surgery. Stress testing should be performed judiciously, especially for those at lower risk and only in those in whom testing would be appropriate, regardless of planned surgery.
When managing patients with complex anatomy or unstable cardiovascular disease, team-based care should be emphasized, the authors note. There are significant perioperative implications for new therapies for management of diabetes, heart failure, and obesity. To minimize the risk for perioperative ketoacidosis associated with their use, sodium glucose-cotransporter 2 inhibitors should be discontinued three to four days before surgery. Myocardial injury after noncardiac surgery is a newly identified disease process, which should not be ignored. The risk for stroke is increased for patients with newly diagnosed atrial fibrillation identified during or after noncardiac surgery. Only patients at highest risk for thrombotic complications should use perioperative bridging of oral anticoagulant therapy.
"This new guideline is a comprehensive review of the latest research to help inform clinicians who manage perioperative patients, with the ultimate goal of restoring health and minimizing cardiovascular complications," Thompson said in a statement.
Several authors disclosed ties to the biopharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Urinary Incontinence Linked to CVD Risk Factors, Comorbid Conditions
FRIDAY, May 2, 2025 -- Urinary incontinence is not associated with moderate-to-vigorous physical activity (MVPA) classification, but is associated with cardiovascular disease...
No Benefit Seen for Revascularization Added to Drug Therapy in Carotid Stenosis
FRIDAY, May 2, 2025 -- For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted stroke risk, there is no...
Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk
MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.